News blog
Maelor
- BY: Andrew Hore |
- POSTED: 11/02/2008 |
Hospital medicines supplier Maelor has launched its new treatment ahead of schedule.
Maelor acquired the UK rights to Aloxi, a treatment for nausea and vomiting brought on by chemotherapy, from Helsinn last October. A March 2008 launch was pencilled in but Maelor has got it onto the market a few weeks earlier.
A 10% market share for Aloxi would generate revenues of more than £3m. It costs more than the main rivals but it is more efficient and works for longer. Forecast group revenues are £6.5m for the year to March 2008 so that shows how significant Aloxi could be when it generates revenues.
Maelor has a solid portfolio of products that generate revenues and are profitable. On top of that there are others in development to provide potential upside. That is different to most small health and pharma companies which don’t tend to have enough revenues to cover their costs and which concentrate on products which are yet to see the light of day.
A 2007-08 profit of £1.6m is forecast. At 12.5p, the shares are trading on 11 times prospective earnings, falling to nine next year.
© 2024 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
- Browse by issue
- All issues
- Popular tags
- All tags
- AIM Micro feeds
Keep up to date with articles published at AIMMicro.com. Subscribe to AIM Micro RSS Feeds
|